



AstraZeneca strives to be a scientific leader in hematology by helping to transform care for the **3.6 million people living with blood cancers*** worldwide as of 2020.¹

*Blood cancers including leukemia, lymphoma and myeloma.

Delivering Innovative Medicines



Leveraging our **40+ years heritage in oncology**, we're developing innovative **blood cancer treatments** that seek to address critical unmet medical needs across our **six signature scientific platforms**²:

- Antibody drug conjugates
- Cell therapy
- Epigenetics
- Immuno-oncology
- DNA damage response
- Tumor drivers and resistance



We are **actively investigating eight molecules** in the clinic across various blood cancers.³ Our robust pipeline allows us to explore within **three major categories** of hematologic malignancies, including leukemia, lymphoma and myeloma.



Our robust development program includes **more than 20 company-sponsored clinical trials**³ with a goal of developing new medicines to potentially reach over **300,000 patients in over 70 countries** by 2030.



Among hematologic malignancies, **our core areas of focus** include AML, MDS, CLL, DLBCL, MCL and MM.*

*AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma.

Taking Courageous, Science-Driven Risks

AstraZeneca is guided first and foremost by science. We are bold and fearless in our approach, innovative in our mindset and committed to improving the lives of patients.

Our key research principles include:



Exploring multiple mechanisms of action— finding therapeutic mechanisms validated in solid tumors that have potential application for blood cancers.



Looking big and small— following the science to transform patient care where unmet needs exists, no matter how big or small the patient population.



Uncovering new approaches— encouraging scientific exploration with a smart risk-taking process that allows us to adapt and evolve, accelerating programs that show promise.

Shaped by the Blood Cancer Community

Each person impacted by blood cancer, whether they are a patient, caregiver, family member or friend, is another reason our researchers work every day to advance the science in hematology. We're proud to be part of and to collaborate with the blood cancer community, integrating patient insights at key decision points of development, to help transform healthcare delivery and create new treatment options for those battling blood cancers.



References

1. World Health Organization. Worldwide Cancer Fact Sheet 2020 (Incidence, Mortality and Prevalence by cancer site). <https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf>. Accessed May 2022. 2. AstraZeneca. Oncology - Our Therapy Areas. <https://www.astrazeneca.com/our-therapy-areas/oncology.html>. Accessed May 2022. 3. AstraZeneca. Clinical Trials Appendix, Q1 2021 Results Update. https://www.astrazeneca.com/content/dam/az/PDF/2021/q1-2021/Q1_2021_results_clinical_trials_appendix.pdf. Accessed May 2022.